S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Aeterna Zentaris (AEZS) Competitors

$2.22
-0.17 (-7.10%)
(As of 12/8/2023 ET)
Compare
Today's Range
$2.17
$2.42
50-Day Range
$1.42
$2.39
52-Week Range
$1.36
$4.00
Volume
21,393 shs
Average Volume
11,892 shs
Market Capitalization
$10.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

AEZS vs. ARAV, KZIA, VCNX, NRSN, NHWK, EDSA, ABVC, VIRI, ASLN, and TENX

Should you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Aravive (ARAV), Kazia Therapeutics (KZIA), Vaccinex (VCNX), NeuroSense Therapeutics (NRSN), NightHawk Biosciences (NHWK), Edesa Biotech (EDSA), ABVC BioPharma (ABVC), Virios Therapeutics (VIRI), ASLAN Pharmaceuticals (ASLN), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical preparations" industry.

Aeterna Zentaris vs.

Aravive (NASDAQ:ARAV) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

28.5% of Aravive shares are held by institutional investors. Comparatively, 0.6% of Aeterna Zentaris shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Comparatively, 0.1% of Aeterna Zentaris shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aravive currently has a consensus target price of $12.25, indicating a potential upside of 9,323.08%. Aeterna Zentaris has a consensus target price of $15.00, indicating a potential upside of 574.16%. Given Aeterna Zentaris' higher probable upside, equities research analysts clearly believe Aravive is more favorable than Aeterna Zentaris.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aravive
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
Aeterna Zentaris
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Aeterna Zentaris received 315 more outperform votes than Aravive when rated by MarketBeat users. Likewise, 64.17% of users gave Aeterna Zentaris an outperform vote while only 62.28% of users gave Aravive an outperform vote.

CompanyUnderperformOutperform
AraviveOutperform Votes
104
62.28%
Underperform Votes
63
37.72%
Aeterna ZentarisOutperform Votes
419
64.17%
Underperform Votes
234
35.83%

Aeterna Zentaris has lower revenue, but higher earnings than Aravive. Aeterna Zentaris is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aravive$9.14M1.05-$76.32M-$0.96-0.14
Aeterna Zentaris$6.86M1.57-$22.73M-$4.81-0.46

Aeterna Zentaris has a net margin of -340.56% compared to Aeterna Zentaris' net margin of -569.65%. Aravive's return on equity of -49.10% beat Aeterna Zentaris' return on equity.

Company Net Margins Return on Equity Return on Assets
Aravive-569.65% -1,865.78% -99.65%
Aeterna Zentaris -340.56%-49.10%-30.61%

In the previous week, Aravive and Aravive both had 1 articles in the media. Aeterna Zentaris' average media sentiment score of 0.98 beat Aravive's score of 0.00 indicating that Aravive is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aravive
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aeterna Zentaris
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aravive has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Summary

Aravive and Aeterna Zentaris tied by winning 8 of the 16 factors compared between the two stocks.


Get Aeterna Zentaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AEZS vs. The Competition

MetricAeterna ZentarisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$10.81M$5.23B$4.63B$6.73B
Dividend YieldN/A2.94%3.00%5.95%
P/E Ratio-0.4612.21130.2714.26
Price / Sales1.572,842.173,096.93552.98
Price / CashN/A17.1121.7423.12
Price / Book0.304.484.734.65
Net Income-$22.73M$199.40M$125.01M$177.06M
7 Day Performance8.27%2.07%1.06%0.80%
1 Month Performance47.96%8.90%7.15%7.10%
1 Year Performance-42.51%13.02%11.33%7.58%

Aeterna Zentaris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARAV
Aravive
2.397 of 5 stars
$0.13
-7.1%
$12.25
+9,258.3%
-90.8%$10.09M$6.99M-0.1423News Coverage
Gap Down
KZIA
Kazia Therapeutics
2.068 of 5 stars
$0.64
+6.7%
$2.00
+212.5%
-28.3%$10.46M$20,000.000.002,021Gap Up
VCNX
Vaccinex
0 of 5 stars
$0.85
-1.2%
N/A-94.1%$10.60M$280,000.00-0.1438
NRSN
NeuroSense Therapeutics
0 of 5 stars
$0.89
+6.0%
N/A-51.4%$9.68MN/A-0.6914Gap Up
NHWK
NightHawk Biosciences
0 of 5 stars
$0.36
-5.2%
N/A-66.2%$9.51M$6.38M-0.1877News Coverage
Negative News
EDSA
Edesa Biotech
2.1945 of 5 stars
$3.15
+0.3%
$33.50
+963.5%
-34.9%$9.49MN/A-1.2516Upcoming Earnings
ABVC
ABVC BioPharma
0 of 5 stars
$1.50
-10.7%
N/A-82.4%$10.85M$970,000.00-0.4219
VIRI
Virios Therapeutics
0 of 5 stars
$0.58
flat
N/A+146.5%$11.07MN/A-1.744News Coverage
ASLN
ASLAN Pharmaceuticals
1.9075 of 5 stars
$0.68
-6.8%
$15.67
+2,203.9%
-80.2%$11.12MN/A-0.2334Gap Down
TENX
Tenax Therapeutics
1.9902 of 5 stars
$0.38
-5.0%
$6.00
+1,478.9%
-89.5%$9.07MN/A0.007Gap Down

Related Companies and Tools

This page (NASDAQ:AEZS) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -